<DOC>
	<DOCNO>NCT01682772</DOCNO>
	<brief_summary>This open-label , single arm , two part adaptive design phase II trial Olaparib patient advance castration resistant prostate cancer . The trial aim evaluate anti-tumour activity Olaparib metastatic castration resistant prostate cancer , identify molecular signature tumour cell respond non-responding patient , identify predictive biomarkers Olaparib response .</brief_summary>
	<brief_title>TOPARP : A Phase II Trial Olaparib Patients With Advanced Castration Resistant Prostate Cancer</brief_title>
	<detailed_description>Patients advanced castration resistant prostate cancer receive single agent Olaparib dose 400mg twice daily , continuously 28 day cycle . Olaparib administer objective disease progression unacceptable toxicity patient withdrawal whatever reason</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Olaparib</mesh_term>
	<criteria>1 . Subject capable understanding &amp; comply protocol requirement &amp; sign inform consent form 2 . Minimum age 18 year 3 . Histologically confirm adenocarcinoma prostate tumour tissue available molecular analysis 4 . At least one two previous taxanebased chemotherapy regimen . If docetaxel chemotherapy use , consider one regime . Patients may prior exposure cabazitaxel treatment 5 . At least 28 day since completion prior therapy , include major surgery , chemotherapy &amp; investigational agent . Clinically relevant sequela resolve grade 1 less prior recommencing treatment . For hormonal treatment &amp; radiotherapy refer protocol guideline 6 . Documented prostate cancer progression describe protocol . 7 . Surgically medically castrate , testosterone level &lt; 50 ng/dL ( &lt; 2.0 nM ) . If patient treat LHRH agonist must initiate least 4 week prior Cycle 1 Day 1 &amp; must continue throughout study . 8 . Eastern Cooperative Oncology Group Performance Status 0 , 1 , 2 9 . Life expectancy &gt; 12 week 10 . Able swallow whole tablet 11 . Patient &amp; patient 's partner childbearing potential , must agree use medically accept method contraception course study &amp; 3 month last dose study drug 12 . Agreeable biomarker study include pair fresh tumour biopsy . 13 . CTC count 5 cells/7.5mls blood screen 14 . Adequate bone marrow , hepatic &amp; renal function define protocol 1 . Surgery , local prostatic intervention ( exclude prostatic biopsy ) less 28 day Cycle 1 Day 1 2 . Less 28 day active anticancer therapy investigational agent . For hormonal treatment &amp; radiotherapy refer guideline outline inclusion criterion 3 . Prior treatment PARP inhibitor , platinum , cyclophosphamide mitoxantrone chemotherapy 4 . Uncontrolled intercurrent illness include , limited , active infection , symptomatic congestive heart failure ( New York Heart Association Class III IV heart disease ) , unstable angina pectoris , cardiac arrhythmia , uncontrolled hypertension psychiatric illness/social situation would limit compliance study requirement 5 . Any acute toxicity due prior chemotherapy &amp; / radiotherapy resolve NCICTCAE v4.02 grade 0 1 exception chemotherapy induce alopecia &amp; grade 2 peripheral neuropathy 6 . Malignancy within previous 2years &gt; 30 % probability recurrence within 12 month exception nonmelanoma skin cancer , insitu superficial bladder cancer 7 . Patients myelodysplastic syndrome/acute myeloid leukaemia 8 . Patients know symptomatic brain metastasis suitable enrollment . Patients asymptomatic , stable , treated brain metastasis eligible study entry 9 . Patients symptomatic impending cord compression unless appropriately treat beforehand &amp; clinically stable &amp; asymptomatic 10 . Patients experienced seizure seizure within 6 month study treatment currently treat cytochrome P450 enzyme induce antiepileptic drug seizures 11 . Patients receive follow class inhibitor CYP3A4 ( see protocol guideline &amp; wash period ) 12 . Patients gastrointestinal disorder likely interfere absorption study medication 13 . Initiating bisphosphonate therapy adjust bisphosphonate dose/regimen within 30 day prior Cycle 1 Day 1 . Patients stable bisphosphonate regimen eligible &amp; may continue 14 . Presence condition situation , , may put patient significant risk , confound study result , interfere significantly participation study</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Olaparib</keyword>
	<keyword>Adenocarcinoma</keyword>
	<keyword>Prostate</keyword>
</DOC>